Results 131 to 140 of about 462 (190)

Rewiring the immune response in lung cancer: current progress in bispecific antibodies, CAR-T therapy, and the rise of <i>in vivo</i> CAR-T platforms. [PDF]

Front Immunol
He L, Sun Y, Ma B, Lang G, Wen J, Blumenschein GR, Ma H.   +6 more
europepmc   +1 more source

Tough art and microbial drama. [PDF]

Emerg Infect Dis, 2012
Potter P.
europepmc   +1 more source

Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. [PDF]

Clin Cancer Res
Negrao MV, Paula AG, Molkentine D, Hover L, Nilsson M, Vokes N, Engstrom L, Calinisan A, Briere DM, Waters L, Hallin J, Diao L, Altan M, Blumenschein GR, Skoulidis F, Wang J, Kopetz SE, Hong DS, Gibbons DL, Olson P, Christensen JG, Heymach JV.   +21 more
europepmc   +1 more source

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). [PDF]

J Immunother Cancer
Davar D, Cavalcante L, Lakhani N, Moser J, Millward M, McKean M, Voskoboynik M, Sanborn RE, Grewal JS, Narayan A, Patnaik A, Gainor JF, Sznol M, Enstrom A, Blanchfield L, LeBlanc H, Thomas H, Chisamore MJ, Peng SL, Naumovski A.   +19 more
europepmc   +1 more source

Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. [PDF]

J Immunother Cancer
Zhou N, Leung CH, William WN, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Tran HT, Wu J, Solis Soto LM, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T.   +36 more
europepmc   +1 more source

A gut microbial signature for combination immune checkpoint blockade across cancer types. [PDF]

Nat Med
Gunjur A, Shao Y, Rozday T, Klein O, Mu A, Haak BW, Markman B, Kee D, Carlino MS, Underhill C, Frentzas S, Michael M, Gao B, Palmer J, Cebon J, Behren A, Adams DJ, Lawley TD.   +17 more
europepmc   +1 more source

Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study. [PDF]

EClinicalMedicine
Borgers JSW, Johnson DB, Livingstone E, Schadendorf D, Buchbinder EI, Haydu LE, Gohil L, Robinson WA, Mehmi I, Hamid O, Ferreira M, Salama AKS, Dimitriou F, Carlino MS, Long GV, Ascierto PA, Simeone E, Najjar YG, Hospers GAP, Choi J, Chandra S, Wayne JD, García CIR, Xu W, Lebbé C, Da-Meda L, Atkinson V, Mckean M, Forschner A, Asare EA, Daletzakis A, Taylor JS, Amant F, Tsai KK, Eroglu Z, Haanen JBAG, Glitza de Oliva IC.   +36 more
europepmc   +1 more source

Harnessing CD8 T cell responses using PD-1-IL-2 combination therapy. [PDF]

Trends Cancer
Hashimoto M, Ramalingam SS, Ahmed R.
europepmc   +1 more source

A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation. [PDF]

Cancer Discov
Yaeger R, McKean MA, Haq R, Beck JT, Taylor MH, Cohen JE, Bowles DW, Gadgeel SM, Mihalcioiu C, Papadopoulos KP, Diamond EL, Sturtz KB, Feng G, Drescher SK, Reddy MB, Sengupta B, Maity AK, Brown SA, Singh A, Brown EN, Baer BR, Wong J, Mou TC, Wu WI, Kahn DR, Gadal S, Rosen N, Gaudino JJ, Lee PA, Hartley DP, Rothenberg SM.   +30 more
europepmc   +1 more source

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors. [PDF]

Front Oncol
Shimizu T, Powderly J, Abdul Razak A, LoRusso P, Miller KD, Kao S, Kongpachith S, Tribouley C, Graham M, Stoll B, Patel M, Sahtout M, Blaney M, Leibman R, Golan T, Tolcher A.   +15 more
europepmc   +1 more source